These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38751245)

  • 1. A systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies.
    Carrillo de Albornoz S; Chai KL; Higgins AM; Petrie D; Wood EM; McQuilten ZK
    Int J Technol Assess Health Care; 2024 May; 40(1):e32. PubMed ID: 38751245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies.
    Carrillo de Albornoz S; Higgins AM; Petrie D; Irving A; Fanning L; Weinkove R; Crispin P; Dendle C; Gilbertson M; Johnston A; Keegan A; Pepperell D; Pullon H; Reynolds J; van Tonder T; Trotman J; Waters N; Wellard C; Weston H; Morrissey CO; Wood EM; McQuilten ZK
    Blood Adv; 2024 May; 8(9):2259-2267. PubMed ID: 38484199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies.
    Beauté J; Levy P; Millet V; Debré M; Dudoit Y; Le Mignot L; Tajahmady A; Thomas C; Suarez F; Pellier I; Hermine O; Aladjidi N; Mahlaoui N; Fischer A;
    Clin Exp Immunol; 2010 May; 160(2):240-5. PubMed ID: 20041884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
    Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
    Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain.
    Alsina L; Montoro JB; Moral PM; Neth O; Pica MO; Sánchez-Ramón S; Presa M; Oyagüez I; Casado MÁ; González-Granado LI
    Eur J Health Econ; 2022 Apr; 23(3):551-558. PubMed ID: 34546485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
    Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
    J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.
    Martin A; Lavoie L; Goetghebeur M; Schellenberg R
    Transfus Med; 2013 Feb; 23(1):55-60. PubMed ID: 23167310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.
    Piscitelli E; Massa M; De Martino BM; Serio CS; Guglielmi G; Colacicco G; Tuccillo F; Habetswallner F
    Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e115-e119. PubMed ID: 33122403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia?
    Noto A; Cassin R; Mattiello V; Bortolotti M; Reda G; Barcellini W
    Front Immunol; 2023; 14():1062376. PubMed ID: 37122737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.
    Perraudin C; Bourdin A; Spertini F; Berger J; Bugnon O
    J Clin Immunol; 2016 Jul; 36(5):502-10. PubMed ID: 27139500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinician survey for management of the secondary immunodeficiency caused by hematological malignancies in China.
    Ye C; Liu J; Song X; Zheng S; Liu J
    Medicine (Baltimore); 2021 Jan; 100(3):e23935. PubMed ID: 33545966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin utilization in Canada: a comparative analysis of provincial guidelines and a scoping review of the literature.
    Harmon M; Riazi K; Callum J; Arnold DM; Barty R; Sidhu D; Heddle NM; MacLeod L; Li N
    Allergy Asthma Clin Immunol; 2023 Sep; 19(1):85. PubMed ID: 37717038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin for multifocal motor neuropathy.
    Keddie S; Eftimov F; van den Berg LH; Brassington R; de Haan RJ; van Schaik IN
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD004429. PubMed ID: 35015296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
    Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
    Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Natural History of Untreated Primary Hypogammaglobulinemia in Adults: Implications for the Diagnosis and Treatment of Common Variable Immunodeficiency Disorders (CVID).
    Ameratunga R; Ahn Y; Steele R; Woon ST
    Front Immunol; 2019; 10():1541. PubMed ID: 31379811
    [No Abstract]   [Full Text] [Related]  

  • 16. Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological malignancy.
    Windegger TM; English J; Weston H; Morwood K; Kynn M; Scuffham P; Fung YL
    Asia Pac J Clin Oncol; 2021 Dec; 17(6):546-554. PubMed ID: 33460509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia.
    Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
    Blood Transfus; 2020 Mar; 18(2):96-105. PubMed ID: 32271703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
    Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
    Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic immunoglobulin maintenance therapy in myasthenia gravis.
    Alcantara M; Sarpong E; Barnett C; Katzberg H; Bril V
    Eur J Neurol; 2021 Feb; 28(2):639-646. PubMed ID: 32964565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis.
    Soares MO; Welton NJ; Harrison DA; Peura P; Shankar- Hari M; Harvey SE; Madan JJ; Ades AE; Palmer SJ; Rowan KM
    Health Technol Assess; 2012; 16(7):1-186. PubMed ID: 22361003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.